Adrixetinib clinical trials
Adrixetinib is named as an intervention in 2 current clinical trials in our USA, South Korea and Spain registers. 1 is recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Qurient Co., Ltd. The most-studied condition is Esophageal Cancer.
How Adrixetinib works
All drug targets →- Graft versus host diseasePhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314452, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12375, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Adrixetinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Adrixetinib
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
NCT07138196 · ClinicalTrials.gov ↗ · Chronic Graft-Versus-Host Disease
|
Phase 1 | Recruiting | Qurient Co., Ltd | Spain |
|
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
NCT05438420 · Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer
|
Phase 1/2 | Active, closed | Qurient Co., Ltd | USA, South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Adrixetinib
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Qurient Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in South Korea | 1 | 0 |
| Clinical trials in Spain | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Adrixetinib trials
How many clinical trials are testing Adrixetinib?
2 current trials in our USA, South Korea and Spain registers name Adrixetinib (also registered as Q702) as a drug or biological intervention, as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.
Are Adrixetinib trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Spain. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Adrixetinib clinical trials?
The lead sponsor is Qurient Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Adrixetinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adrixetinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adrixetinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.